17 October 2024 The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in 2023 to $30.8 billion in 2033, driven by the launch of the first biologic for COPD and other pioneering pipeline agents.
As the European Parliament prepares for the confirmation hearings of the new Commissioners, the Open Trade Coalition is reiterating its call for a bold and open EU trade policy, according to a posting on the European Federation of Pharmaceutical Industries and Associations (EFPIA) website. 18 October 2024
After a couple of negative decisions, the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). 18 October 2024
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Austrian drug developer Marinomed Biotech has entered a new collaboration and licensing agreement with Chinese drugmaker Luoxin Pharmaceutical Group. 21 October 2021
Italian ophthalmics company SIFI has announced positive results from a Phase III study of its polihexanide-based therapy for people with acanthamoeba keratitis (AK). 20 October 2021
Following recent discussions with the US regulator, Sage Therapeutics and partner Biogen said yesterday they plan to submit a New Drug Application (NDA) to the US Food and Drug Administration for zuranolone (SAGE-217), an investigational two-week, once-daily therapeutic, in the second half of 2022. 20 October 2021
Japanese drugmaker Sumitomo Dainippon Pharma and Nashville, USA-based BehaVR have signed definitive agreements to develop and commercialize both prescription digital therapeutics and general wellness products for treatment of social anxiety disorder (SAD), generalized anxiety disorder (GAD), and major depressive disorder (MDD) with the goal of bringing much needed tools to tackle the escalating global anxiety and depression crisis. 20 October 2021
US health care giant Johnson & Johnson today was the first pharma to report third-quarter 2021 financials, noting that group sales for the period were up 10.7% at $23.34 billion, but missed analysts’ expectations of $23.72 billion. 19 October 2021
AI-driven drug combo specialist Pharnext saw its shares leap nearly a tenth in morning trading on Tuesday, after a positive result from the Phase III PLEO-CMT trial. 19 October 2021
Californian precision oncology company Calithera Biosciences has padded its pipeline with two assets from Japanese giant Takeda Pharmaceutical. 19 October 2021
The Russian government has officially presented a new state program for the development of the domestic pharmaceutical industry for the next 10 years - "Pharma-2030," reports The Pharma Letter’s local correspondent. 19 October 2021
US pharma giant Merck & Co and Ridgeback Biotherapies’ investigational oral antiviral molnupiravir that reduced the risk of hospitalization or death by approximately 50% compared to a placebo has got five Indian companies rushing to collaborate on the oral antiviral medicine. 19 October 2021
Shares of USA-based antibacterial products developer Entasis Therapeutics were up 27% at $3.95 pre-market, as the company announced positive top-line results from its ATTACK trial - a global Phase III registrational trial evaluating the safety and efficacy of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with infections caused by Acinetobacter baumannii. 19 October 2021
A positive reimbursement decision in the UK will see patients in England and Wales gain access to Boehringer Ingelheim’s Ofev (nintedanib) through the country’s national healthcare provider. 18 October 2021
Physics-based US software specialist Schrödinger and Centessa Pharmaceuticals, together with the latter’s subsidiary Orexia Therapeutics, today announced an exclusive collaboration focused on the discovery of novel therapeutics targeting the orexin-2 receptor (OX2R). 18 October 2021
China’s Center for Drug Evaluation (CDE), a division under the Chinese drug industry watchdog the National Medical Products Administration (NMPA), has been churning out guidelines in the past year to help the nation transform from a generics/biosimilar maker into a novel drug development hub, reports The Pharma Letter’s local correspondent. 18 October 2021
Oyster Point Pharma saw its shares gain almost 12% to $15.30 pre-market today, as it revealed that the US the Food and Drug Administration has approved Tyrvava (varenicline solution) Nasal Spray 0.03mg for the treatment of the signs and symptoms of dry eye disease. 18 October 2021
Irish pharmaceuticals trade group the IPHA has welcomed the provision of 30 million euros ($35 million) for new medicines in the Government’s recent budget. 18 October 2021
Highlighting research presented at the Infectious Diseases Week (IDWeek) annual congress, Brighton, UK-based biotech Destiny Pharma says there is “strong support” for the use of its XF-73 nasal product. 18 October 2021
Starting this week, Brazil’s Oswaldo Cruz Foundation (Fiocruz) will be part of a Phase III international multicenter study with the drug molnupiravir. 18 October 2021
New European Union (EU) regulation requires life sciences companies’ data in the clinical trial master file (TMF) to remain secure, accessible, and usable for a period of 25 years. 15 October 2021
USA-based NRx Pharmaceuticals has announced the publication of peer-reviewed results from a prospective, open-label, administratively controlled trial of aviptadil (vasoactive intestinal peptide [VIP] with the proposed trade name Zyesami) for the treatment of respiratory failure in patients with Critical COVID-19. 15 October 2021
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.